Resectable gastric carcinoma
Adult: In combination with tegafur and oteracil potassium: 40 mg/m2 BSA bid for 7 days pre-operatively and for 15 days after operation starting on day 15 after operation.
Indications and Dosage
Oral
Resectable gastric carcinoma Adult: In combination with tegafur and oteracil potassium: 40 mg/m2 BSA bid for 7 days pre-operatively and for 15 days after operation starting on day 15 after operation.
|
Contraindications
Hypersensitivity, Pregnancy and breast-feeding.
|
Special Precautions
Cardiac, renal or hepatic impairment. Monitor CBC durring chemotherapy.
|
Adverse Reactions
Fatigue, diarrhoea, constipation, sore mouth, hair thining, rash, loss of appetite, change in taste, headaches, insomnia, brittle nails, photosensitivity, confusion, drowsiness.
Potentially Fatal: Bone marrow suppression during chemotherapy. |
Drug Interactions
May cause changes in INR readings when used with warfarin. May raise serum phenytoin levels when used concurrently.
|
Action
Description:
Mechanism of Action: Gimeracil strongly inhibits dihydropyrimidine dehydrogenase, and inhibits 5-FU degradation approximately 180 times more effectively than uracil in vitro. Coadministration of gimeracil and tegafur markedly increases the antitumor activity of tegafur. |
MIMS Class
|